Reblozyl
New Therapy for MDS-Related Anemia More Effective Than Standard Epoetin Alfa
The novel therapy luspatercept (Reblozyl, Bristol Myers Squibb) was more effective than epoetin alfa for achieving ...
JANUARY 15, 2024
Luspatercept Reduces Dependence on Blood Transfusions in Patients With MDS
Treatment with luspatercept (Reblozyl, Bristol Myers Squibb) led to significant improvements in red blood cell ...
AUGUST 23, 2023
FDA Approves Reblozyl to Treat Anemia in Some Patients With MDS
The FDA approved luspatercept-aamt (Reblozyl, Celgene) for the treatment of anemia in adults with very low- to ...
APRIL 10, 2020
Load more